沃森生物：子公司玉溪沃森收到13价肺炎结合疫苗埃及上市许可证

Core Viewpoint - Watson Bio's subsidiary, Yuxi Watson, has received a biological product marketing license from the Egyptian Drug Authority for its 13-valent pneumococcal polysaccharide conjugate vaccine, marking a significant step in the company's internationalization strategy and expected to positively impact future annual performance, although actual market launch and sales performance remain uncertain [1] Group 1 - The vaccine is intended for infants and children aged 6 weeks to 5 years to prevent infections caused by 13 serotypes of pneumococcus [1] - The approval of the license is an important milestone in the company's international expansion efforts [1] - The future performance impact on the company is anticipated to be positive, but there is uncertainty regarding the actual launch date and sales outcomes [1]